Drug Type Small molecule-drug conjugates |
Synonyms Hsp90-targeted sn-38 conjugate pen-866, Locnartecan, HDC SN-38 + [4] |
Target |
Mechanism HSP90 inhibitors(Heat shock 90kDa proteins inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC49H49N7O9 |
InChIKeyQTPZAEAYDWMVJO-GGCSAXROSA-N |
CAS Registry1472614-83-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | US | 30 Jan 2022 | |
Solid tumor | Phase 2 | US | 30 Jan 2022 | |
Advanced cancer | Phase 2 | US | 29 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 29 Aug 2017 | |
Cervical Squamous Cell Carcinoma | Phase 2 | US | 29 Aug 2017 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | US | 29 Aug 2017 | |
Pancreatic Ductal Adenocarcinoma | Phase 2 | US | 29 Aug 2017 | |
Small Cell Lung Cancer | Phase 2 | US | 29 Aug 2017 | |
squamous cell carcinoma of the anus | Phase 2 | US | 29 Aug 2017 | |
Squamous Cell Carcinoma of the Penis | Phase 2 | US | 29 Aug 2017 |